Schlieren ZH – Hemotune has raised 14 million Swiss francs in a series B2 financing. The medtech company intends to use the fresh capital to take the HemoSystem blood purification system into the clinical phase.
Hemotune, a medtech company based in Schlieren, has closed a Series B2 financing of 14 million Swiss francs. According to a press release, the investment was led by Belmondo. It was supported by VP Venture Partners, HEMEX, Occident, Zürcher Kantonalbank (ZKB) and the Geneva-based investment company EFI. The investment will enable hemotune to take its HemoSystem blood purification system into the clinical phase.
Hemotune, a spin-off of the Swiss Federal Institute of Technology in Zurich(ETH), has succeeded in using the system to remove large biomolecules directly from patients' blood. The use of HemoSystem is initially focused on the treatment of immunodepression caused by sepsis. Further use at a later date is not ruled out. With 11 million deaths a year as a result of severe sepsis, the technology developed by hemotune is important for both patients and healthcare systems.
"I am very proud of our team's achievements in completing the preclinical development of the HemoSystem," Lukas Langenegger, CEO and co-founder of hemotune AG, is quoted as saying in the press release. "The success of our Series B2 funding round underlines not only the potential of our innovative blood purification platform, but also the confidence our investors have in our team and our vision to revolutionize medical treatment." Dr. Darius Madjdpour, founder of Belmondo, was impressed by the development of hemotune over the past seven years: "We are delighted to support the team on its further journey and look forward to seeing how the product will spread worldwide and help many patients in the coming years." ce/ww